Table 1.
Potential GBM treatments currently in clinical trial.
| Treatment | Intervention | Molecular target | Clinical phase |
|---|---|---|---|
| TRC105 + Bevacizumab (Avastin) | Antibody + Drug | Endoglin/VEGF | 1 |
| Amgen386 | Antibody | Angiopoietin-1 and -2 | 1 |
| AMG595 | Antibody Drug Conjugate | EGFRvIII | 1 |
| PSMA ADC MMAE | Antibody Drug Conjugate | PSMA/Tubulin | 2 |
| Ketogenic Diet | Dietary Adjustment | N/A | 1 |
| Bevacizumab (Avastin) + TPI 287 | Drug | VEGF/Tubulin | 2 |
| AR-67 | Drug | Topoisomerase 1 | 2 |
| PD 0332991 (Palbociclib) | Drug | Cyclin-dependent Kinase 4/6 | 2 |
| Pazopanib (Votrient) + Topotecan (Hycamtin) | Drug | Tyrosine Kinase Receptors (multiple) + Topoisomerase 1 | 2 |
| G-202 | Drug | Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump | 2 |
| Aldoxorubicin | Drug | DNA | 2 |
| Dovitinib (TKI258) | Drug | FGFR/VEGFR/PDGFR | 1 |
| AG-120 | Drug | IDH-1 R132H | 1 |
| Axitinib (Inlyta) + Radiation Therapy | Drug + Radiation | Tyrosine Kinase Receptors (multiple) | 2 |
| NovoTTF-100A device + TMZ | Electrical device + Drug | N/A | 3 |
| DC-Vax L | Immunotherapy | N/A | 3 |
| HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells | Immunotherapy | N/A | 1 |
| Rindopepimut | Immunotherapy | EGFRvIII | 3 |
| Parvovirus H-1 (ParvOryx) | Virus | N/A | 1 |
| Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine | Virus | N/A | 1 |
| DNX2401 and Temozolomide | Virus + TMZ | N/A | 1 |